In spite of plummeting valuation, 23andMe still aims to pivot into biotech
Listen now
Description
23andMe has seen its valuation plummet from $6 billion to close to zero, with the Nasdaq threatening to delist the company’s stock. Still, company leaders have high hopes for medical research and a pivot to biotech. Rolfe Winkler has been writing about what happened for The Wall Street Journal, and discussed the company’s financial woes and future roadmap with Marketplace’s Lily Jamali.
More Episodes
Robotics company Boston Dynamics announced this month it is retiring its humanoid robot known as “Atlas.” The 6′, 2,330 lb robot was considered a quantum leap in robotics and was famous for parkour stunts and awkward dance moves. Debuting more than a decade ago in 2013, the Atlas robot was a part...
Published 04/29/24
Published 04/29/24
The noncompete clause is dead! American tech workers are poised to benefit from the Federal Trade Commission’s new crackdown on the agreements, which prevent a company’s ex-employees from working for its rivals for a specified time. Also, Tesla’s profits crashed 55%. As electric vehicle sales...
Published 04/26/24
Links
Genres
Artwork or description wrong?
Request an update »
Updates may take a few minutes.
Do you host a podcast?
Track your ranks and reviews from Spotify, Apple Podcasts and more.
See hourly chart positions and more than 30 days of history.
Get Chartable Analytics »
See hourly chart positions and more than 30 days of history.
